bioRxivCancer BiologyPreprint
Unveiling the anti-glioma potential of a marine derivative, Fucoidan: its synergistic cytotoxicity with Temozolomide-an in vitro and in silico experimental study
I. Biswas, D. S. Precilla, S. S. Kuduvalli, M. A. Ramachandran, A. S, V. Raman, D. Prabhu, A. T. S
Abstract
IntroductionGlioma, coined as a "butterfly" tumor associated with a dismal prognosis. Marine algal compounds with the richest sources of bioactive components, act as significant anti-tumor therapeutics. However, there is a paucity of studies conducted on Fucoidan to enhance the anti-glioma efficacy of Temozolomide. Therefore, the present study aimed to evaluate the synergistic anti-proliferative, anti-inflammatory and pro-apoptotic effects of Fucoidan with Temozolomide in in vitro and in silico experimental setup. MethodologyThe anti-proliferative effects of Temozolomide and Fucoidan was evaluated on C6 glioma cells by MTT and migration assay. Modulation of inflammatory markers and apoptosis induction was affirmed at the morphological and transcriptional level, by dual staining and gene expression. Molecular docking (MD) and molecular dynamics simulation (MDS) studies were performed against the targets to rationalize the inhibitory effect. ResultsThe dual-drug combination significantly reduced the cell viability and migration of glioma cells in a synergistic dose-dependent manner. At the molecular level, the dual-drug combination significantly down-regulated inflammatory genes with a concomitant upregulation of pro-apoptotic marker. In consensus with our in vitro findings, molecular docking and simulation studies revealed that the anti-tumor ligands: Temozolomide, Fucoidan with 5-(3-Methy1-trizeno)-imidazole-4-carboxamide (MTIC), and 4-amino-5-imidazole-carboxamide (AIC) had the potency to bind to the inflammatory proteins at their active sites, mediated by H-bonds and other non-covalent interactions. Discussion and ConclusionThe dual-drug combinatorial treatment synergistically inhibited the proliferation, migration of glioma cells and promoted apoptosis; conversely with the down-regulation of inflammatory genes. However, pre-clinical experimental evidence is warranted for the possible translation of this combination.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
- approach: mechanistic / dynamical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A combination of Metformin and Epigallocatechin Gallate Potentiates Glioma Chemotherapy in vivo
S. S. Kuduvalli, D. P. S, … A. T. S·bioRxiv·Nov 16, 2022
- Agonistic CD40 antibody therapy induces tertiary lymphoid structures but impairs the response to immune checkpoint blockade in glioma
L. van Hooren, A. Vaccaro, … A. Dimberg·bioRxiv·Jan 5, 2021
- DIFFERENTIAL ANTIPROLIFERATIVE EFFECTS OF CANNABIDIOL (CBD) IN THE CORE AND INFILTRATIVE BOUNDARY OF HUMAN GLIOBLASTOMA CELLS
Ghazala Abassi-Rana, Yolanda Calle, Francisco Molina‐Holgado·bioRxiv·Sep 17, 2024
- Electromagnetic Field and Temozolomide Increase Differentiation of Human Glioblastoma Cell Line; concise view of mechanism
Meysam Ahmadi-Zeidabadi, Zeinab Akbarnejad, … Hossein Eskandary·bioRxiv·Jun 6, 2018
- Dynamics of repurposing synthetic and natural compounds against WNT/β-Catenin signaling in glioma- An in vivo approach
D. P. S, S. S. Kuduvalli, … A. T. S·bioRxiv·Dec 2, 2022
- Temozolomide-associated inflammatory-repair remodeling in recurrent glioblastoma exposes a ROCK-linked therapeutic vulnerability
Rafał Chojak, Umme Habiba Faisal, … Atique U. Ahmed·bioRxiv·Sep 22, 2026